Table 1.
Baseline characteristics of all 77 patients
| Characteristic | Median (IQR; range) | Mean (95% CI) | n (%) | Missing values |
|---|---|---|---|---|
| Age | 65 (56–70; 32–85) | 61 (61–66) | 0 | |
| Sex | ||||
| Female | 27 (35%) | 0 | ||
| Male | 50 (64%) | 0 | ||
| Body weight (kg) | 96 (86–113; 67–172) | 101 (96–106) | 1 | |
| Body mass index (kg/m2) | 33 (30–39; 25–59) | 35 (34–37) | 1 | |
| Systolic blood pressure (mmHg) | 136 (124–146; 102–198) | 137 (133–142) | 10 | |
| Diastolic blood pressure (mmHg) | 80 (76–88; 55–110) | 81 (79–84) | 10 | |
| Duration of type 2 diabetes (years) | 15 (8.3–21; 2–37) | 15 (13–17) | 1 | |
| Diabetes complications | 57 (74%) | 0 | ||
| Macrovascular | 17 (22%) | |||
| Coronary heart disease | 14 (18%) | |||
| Cerebrovascular disease | 3 (3.9%) | |||
| Microvascular | 55 (71%) | |||
| Retinopathy | 15 (19%) | |||
| Neuropathy | 35 (45%) | |||
| Nephropathy | 35 (45%) | |||
| Duration of preceding GLP-1 analogue therapy (months) | 25 (18–41; 3–72) | 28 (25–32) | 5 | |
| Glycated haemoglobin A1c (HbA1c) | ||||
| % | 8.4 (7.7–9.3; 5.0–12) | 8.3 (8.0–8.6) | 0 | |
| mmol/mol | 68 (60–78; 31–107) | 67 (63–70) | ||
| Preceding GLP-1 analogue | 0 | |||
| Liraglutide | 61 (79.2%) | |||
| Dulaglutide | 11 (14.0%) | |||
| Exenatide | 3 (3.8%) | |||
| Orally administered semaglutide | 2 (2.6%) | |||
| Concomitant oral diabetes medication metformin | 61 (79%) | |||
| Metformin dose (g) | 2.0 (1.0–2.0; 0.5–3.0) | 1.7 (1.6–1.9) | ||
| Pioglitazone | 4 (5.2%) | |||
| Sulfonyl urea | 16 (20.7%) | |||
| SGLT2 inhibitor | 8 (10.3%) | |||
| Concomitant insulin therapy | ||||
| Basal insulin | 56 (72.7%) | |||
| Daily basal insulin dose (IU) | 36 (30–50; 12–145) | 44 (37–51) | ||
| Prandial insulin | 12 (15.5%) | |||
| Daily prandial insulin dose (IU) | 37 (29–44; 12–85) | 37 (27–48) | ||
| Concomitant therapy | ||||
| Aspirin | 37 (48.0%) | |||
| Statin | 62 (80.5%) | |||
| ACE/ARB inhibitor | 59 (76.6%) | |||
Given are median values with interquartile range (IQR), range as well as mean with 95% confidence interval (CI), the number with percentage and number of missing values